Background: GPP is a rare, chronic, neutrophilic skin disease, with limited real-world data characterizing patients with flares and the impact of flares on disease progression and morbidity.
Objective: Describe the clinical characteristics of patients with GPP, comorbidities, disease epidemiology and frequency and severity of flares, and compare patients with GPP with a matched severe psoriasis population.
Methods: In this population-based real-world cohort study an algorithm was developed to identify patients with GPP flares. Three cohorts were identified using the Système National des Données de Santé (SNDS) database covering almost the entire French population; a prevalent cohort (2010-2018), an incident cohort (2012-2015). A severe psoriasis cohort was compared with the GPP incident cohort using propensity score matching.
Results: The prevalent and incident cohorts comprised 4195 and 1842 patients, respectively. In both cohorts, mean age was 58 years; 53% were male. Comorbidities were significantly more common in the incident cohort versus matched psoriasis cohort, respectively, including hypertension (44% vs. 26%), ischaemic heart disease (26% vs. 18%) and hyperlipidaemia (25% vs. 15%). In the incident cohort, the flare rate was 0.1 flares/person-year and 0.4 flares/person-year among the 569 out of 1842 patients hospitalized with flares. These patients had a mean (±SD) stay of 11.6 ± 10.4 days; 25% were admitted to the intensive care unit. In 2017, the cumulative incidence and cumulative GPP age-sex standardized prevalence were 7.1 and 45.2 per million, respectively.
Conclusions: Patients with GPP had a distinct comorbidity profile compared to patients with severe psoriasis, and GPP flares were associated with long hospitalizations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.19901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulation of epidermal barrier function and pathogenesis of psoriasis by serine protease inhibitors.
Front Immunol
December 2024
Shanxi Key Laboratory of Stem Cells for Immunological Dermatosis, Institute of Dermatology, Taiyuan Central Hospital, Taiyuan, China.
Serine protease inhibitors (Serpins) are a protein superfamily of protease inhibitors that are thought to play a role in the regulation of inflammation, immunity, tumorigenesis, coagulation, blood pressure and cancer metastasis. Serpins is enriched in the skin and play a vital role in modulating the epidermal barrier and maintaining skin homeostasis. Psoriasis is a chronic inflammatory immune-mediated skin disease.
View Article and Find Full Text PDFPredictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.
BMC Gastroenterol
December 2024
Formerly Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic de Barcelona, Barcelona, Spain.
Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).
View Article and Find Full Text PDFEfficacy of secukinumab in Takayasu arteritis with myocardial infarction complicated with generalized pustular psoriasis: A case report.
Medicine (Baltimore)
December 2024
Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Rationale: Takayasu arteritis (TAK) is an autoimmune disease that causes chronic inflammation targeting the aortic wall. Since many patients are resistant to steroid treatment, multiple immunosuppressants or interleukin-6 (IL-6) suppression therapy have served as treatment alternatives. However, there are very few reports on the effectiveness of biologics against inflammatory cytokines upstream of IL-6.
View Article and Find Full Text PDFCharacteristics of Patients with Generalized Pustular Psoriasis: A Report of the Polish Generalized Pustular Psoriasis Group.
Dermatol Ther (Heidelb)
December 2024
Department of Dermatology, Institute of Medical Sciences, Medical College of the University of Rzeszów, Rzeszów, Poland.
Article Synopsis
- The study aimed to analyze the demographic and clinical traits of Polish patients with generalized pustular psoriasis (GPP), revealing that most patients are middle-aged women with common comorbidities like hypertension and cardiovascular diseases.
- A total of 90 patients were examined, who had a median GPP duration of 3 years and experienced an average of 2 flares, often requiring hospitalization; main triggers for flares included medications and infections.
- The findings showed significant differences, such as younger patients often having GPP alongside psoriasis vulgaris (PV), highlighting a need for better management due to the high hospitalization rate and recurrent flares.
In-Use Physicochemical Stability of Sandoz Rituximab Biosimilar in 0.9% Sodium Chloride Solution After Prolonged Storage at Room Temperature Conditions.
Drugs R D
December 2024
Medical Oncology, Sandoz GmbH, Holzkirchen, Germany.
Article Synopsis
- This study examined the stability of Sandoz rituximab biosimilar (SDZ-RTX) under various storage conditions, focusing on both in-use and out-of-fridge scenarios to ensure patient safety.
- The researchers subjected two SDZ-RTX batches to long-term refrigeration followed by exposure to higher temperatures and humidity to simulate real-world storage situations.
- Results indicated that SDZ-RTX maintained its physicochemical and biological quality, meeting strict acceptance criteria even after exposure to elevated temperatures, provided it was prepared in a sterile environment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!